Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
WISP2
REST API REST API
Homo sapiens
WISP2 is differentially expressed in 191 experiments: 143 organism parts: skin, adipose tissue, ... (141 more);, 144 disease states: normal, cervical carcinoma, ... (142 more);, 51 cell types 169 cell lines 19 compound treatments and 58 other conditions.
Synonyms CCN5, CT58, CTGF-L
Orthologs Wisp2 (Rattus norvegicus)   WISP2 (Bos taurus)   Wisp2 (Mus musculus)   WISP2 (Gallus gallus)   ENSCING00000006564 (Ciona intestinalis)   ENSCING00000006772 (Ciona intestinalis)   ENSCING00000006549 (Ciona intestinalis)   ENSCING00000005383 (Ciona intestinalis)   wisp2 (Danio rerio)   Ccn (Drosophila melanogaster)   wisp2 (Xenopus laevis)   WISP2 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term plasma membrane, protein binding, cytoplasm, negative regulation of cell proliferation, extracellular region, cell-cell signaling, soluble fraction, insulin-like growth factor binding, cell adhesion, regulation of cell growth, cell surface, signal transduction
InterPro Term VWF_C, Thrombospondin_1_rpt, IGFBP-like
UniProt Accession O76076, Q6PEG3
Search EB-eye ENSG00000064205
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-6573, E-GEOD-2549, E-GEOD-3526, ... (25 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-19397, E-GEOD-19480, ... (24 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-5823, E-GEOD-3529, E-GEOD-20081
DU145
2
E-GEOD-17482, E-GEOD-20089
MCF7
2
E-GEOD-5258, E-MTAB-37
UACC812
2
E-MTAB-37, E-MTAB-62
k562
1
E-MTAB-62
SW1353
1
E-MTAB-37
163 more value(s).


Cell type

studied in E-GEOD-3920, E-MEXP-66, E-GEOD-13987, E-GEOD-11755, E-MEXP-466, ... (28 experiments)

Factor Value U/D Experiments
CD4+ T cell
2
E-MTAB-24, E-MTAB-25
CD8+ T cell
2
E-AFMX-5, E-MTAB-25
stromal cell
1
2
E-GEOD-10797, E-MEXP-2034, E-GEOD-1460
fibroblast
1
2
E-GEOD-3920, E-GEOD-3204, E-GEOD-26672
memory B cell
1
E-TABM-702
naive B cell
1
E-TABM-702
45 more value(s).


Disease state

studied in E-GEOD-3307, E-MEXP-1922, E-GEOD-2508, E-GEOD-15960, E-MEXP-2069, ... (44 experiments)

Factor Value U/D Experiments
cervical carcinoma
3
E-MEXP-1331, E-MTAB-62, E-MTAB-37
lung adenocarcinoma
3
E-MTAB-37, E-GEOD-2514, E-MEXP-231
AIDS-KS, HIV+, nodular (late) stage
2
E-MEXP-66, E-MTAB-62
obesity
2
E-MTAB-62, E-GEOD-2508
colon carcinoma
1
2
E-GEOD-3726, E-MTAB-62, E-MTAB-37
dilated cardiomyopathy
1
E-GEOD-21610
138 more value(s).


Compound treatment

studied in E-MEXP-1269, E-GEOD-4668, E-GEOD-3284, E-GEOD-5741, E-GEOD-412, ... (12 experiments)

Factor Value U/D Experiments
none
4
E-GEOD-4668, E-GEOD-5741, E-GEOD-412, E-GEOD-5824
5-aza-2'-deoxycytidine
2
1
E-MEXP-1269
control for EGF
1
E-GEOD-6462
glutamine
1
E-MEXP-1335
dimethyl sulfoxide
1
E-GEOD-5824
LDL
1
E-GEOD-5741
13 more value(s).


Biosource provider

studied in E-MTAB-37, E-GEOD-14359

Factor Value U/D Experiments
Provitro GmbH, Berlin, Germany
1
E-GEOD-14359
DMSZ
1
E-MTAB-37
ECACC
1
E-MTAB-37
Charite Universitätsmedizin Berlin
1
E-GEOD-14359


BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-TABM-234, E-GEOD-19743, E-GEOD-21589, E-GEOD-16363

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, E-GEOD-4667, E-MEXP-958, ... (6 experiments)

Disease staging
studied in E-GEOD-19743, E-GEOD-22544, E-TABM-147, E-GEOD-21138, E-GEOD-19665 ... (5 experiments)

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-GEOD-6431

Genotype
studied in E-GEOD-17476, E-GEOD-2292, E-TABM-321, E-GEOD-2724, E-GEOD-2725, ... (8 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-13073, E-GEOD-5681, E-MEXP-1446, E-GEOD-22278, ... (7 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-5764, E-MEXP-2069, E-GEOD-1926, ... (24 experiments)

Infection
studied in E-GEOD-980

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Material type
studied in E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-GEOD-426

Organism status
studied in E-GEOD-19188

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Phenotype
studied in E-GEOD-1309, E-GEOD-21750, E-GEOD-1657

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343, ... (6 experiments)

Qpcr egfr dct
studied in E-GEOD-5851

Replicate
studied in E-GEOD-10797

RNAi
studied in E-MEXP-101, E-GEOD-3697

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-20114

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-TABM-276

Treatment
studied in E-GEOD-22152, E-GEOD-16837, E-GEOD-19246, E-GEOD-19136, E-GEOD-19815 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 00 005
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.282 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM